Explore more publications!

French Industry Network: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Industry Network.

Press releases published on September 22, 2025

Atlas Power and Sovereign Digital Infrastructure Execute MOU to Advance Domestic Canadian AI Data Center Infrastructure
NoPayn Turns Frustration into Innovation with Radical Transparency Approach
Madhya Pradesh Tourism Showcases Heritage, Wilderness, and Culture on the Global Stage at IFTM Top Resa 2025
GENFIT : Résultats financiers du premier semestre 2025 et point sur les activités de la Société
GENFIT Reports First-Half 2025 Financial Results and  Provides Corporate Update
Apex Invest Digital reveals new eBook on the future of global payments
From Catwalk to Sidewalk: How Gensmo Is Disrupting Fashion Week with a 'Brand Playground'
Guerbet : Change in General Management
Guerbet : Evolution de la Direction Générale
Terra Firma Energy Limited Appoints EDF as Optimisation Partner Across its UK Based Flexible Generation Portfolio
InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease  at the MDS 2025 Conference
Sonar Clarity (Avanoo) annonce une levée de fonds auprès d’Auriga Cyber Ventures pour lancer sa nouvelle stratégie de croissance en Europe
CellProthera announces peer-reviewed publication of its Phase I/IIb results on safety and feasibility of ProtheraCytes® in patients with severe heart failure post-myocardial Infarction
CellProthera annonce la publication de ses résultats de phase I/IIb sur la sécurité et la faisabilité des ProtheraCytes® chez des patients souffrant d'insuffisance cardiaque sévère après un infarctus du myocarde.
Helio Diagnostics: A European CDMO dedicated to In Vitro Diagnostics
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the  September 30th General Meeting
Deux agences internationales de conseil en vote soutiennent le projet de gouvernance proposé par OSE Immunotherapeutics à l’Assemblée Générale du 30 septembre
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
L’essai de Phase II LANTIC d’Ipsen en esthétique démontre un profil clinique différencié à longue durée d'action, premier de sa classe pour l'IPN10200, permettant le lancement de l’étude de Phase III
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions